{
  "meta": {
    "title": "30_Inflammatory_Bowel_Disease_-_Complications_And_Treatment",
    "url": "https://brainandscalpel.vercel.app/30-inflammatory-bowel-disease-complications-and-treatment-38660f9d.html",
    "scrapedAt": "2025-11-30T12:28:35.211Z"
  },
  "questions": [
    {
      "text": "A patient with inflammatory bowel disease presents with the following lesion. Which of the following is incorrect regarding this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Can occur years before the onset of bowel symptoms"
        },
        {
          "id": 2,
          "text": "Steroids should be avoided"
        },
        {
          "id": 3,
          "text": "Can develop years after colectomy"
        },
        {
          "id": 4,
          "text": "Associated with severe disease"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given image shows&nbsp;<strong>pyoderma gangrenosum</strong>. It is very difficult to <strong>treat</strong> and often requires IV antibiotics and IV<strong> glucocorticoids</strong>.&nbsp;Other drugs used in its management include dapsone, cyclosporine, and infliximab.</p>\n<p>Pyoderma gangrenosum is a dermatological<strong> extraintestinal manifestation </strong>of inflammatory bowel disease. It begins as a pustule and progresses to an ulcer with necrotic tissue and exudates. It may occur years before the onset of bowel symptoms and is usually <strong>associated with severe disease.</strong></p>\n<p>Lesions are commonly found on the dorsal surface of the feet and legs but may occur on the arms, chest, and even the face. It <strong>responds poorly to colectomy&nbsp;</strong>and may&nbsp;even develop years after the surgery.</p>\n<p>Other dermatological manifestations associated with IBD include:</p>\n<ul>\n<li>Erythema nodosum</li>\n<li>Sweet syndrome (neutrophilic dermatosis)</li>\n<li>Perianal skin tags</li>\n<li>Psoriasis</li>\n<li>Metastatic Crohn's disease (cutaneous granulomas).</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/33a63f2c81144a7ead5aec64462f0d7e.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0341",
      "difficulty": "medium"
    },
    {
      "text": "A 37-year-old man presented with hematuria and dysuria for 5 days. He also complains of chronic diarrhea and weight loss for 6 months. His urine microscopy revealed the following stones. What is the most likely disorder associated with this finding?",
      "choices": [
        {
          "id": 1,
          "text": "Crohn’s disease"
        },
        {
          "id": 2,
          "text": "Ulcerative colitis"
        },
        {
          "id": 3,
          "text": "Irritable bowel syndrome"
        },
        {
          "id": 4,
          "text": "Lactose intolerance"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given urinary crystal is the&nbsp;bipyramidal&nbsp;or&nbsp;envelope-shaped crystals of<strong>&nbsp;</strong>calcium<strong> oxalate</strong> dihydrate. Calcium<strong> oxalate </strong>stones&nbsp;are more commonly associated with <strong>Crohn's disease</strong>.</p>\n<p>In Crohn's disease (especially post small bowel resection), fatty acids are not absorbed because of <strong>ileal dysfunction.</strong> These fatty acids in the gut lumen bind to calcium. Because of this, the dietary oxalates which normally bind to the calcium are now left unbound. This leads to <strong>increased absorption of dietary oxalates</strong> leading to hyperoxaluria and oxalate stones.</p>\n<p>Note: Celiac disease is also associated with calcium oxalate stones.</p><hr><h3>Related Pearl: Inflammatory Bowel Disease (IBD)</h3><p> </p>\n<table>\n<tbody>\n<tr>\n<td> </td>\n<td><strong>Crohn's disease</strong></td>\n<td><strong>Ulcerative colitis</strong></td>\n</tr>\n<tr>\n<td><strong>Age of onset </strong></td>\n<td>2nd-4th decades &amp; 7th-9th decades</td>\n<td>2nd-4th decades &amp; 7th-9th decades </td>\n</tr>\n<tr>\n<td><strong>Most common presentation</strong></td>\n<td>Ileocolitis with rectal sparing</td>\n<td>Proctitis (rectum)</td>\n</tr>\n<tr>\n<td><strong>Protective factors</strong></td>\n<td> None </td>\n<td>\n<p>Smoking </p>\n<p>Appendicectomy</p>\n</td>\n</tr>\n<tr>\n<td><strong>Risk factors</strong></td>\n<td>\n<p>OCP</p>\n<p>Smoking</p>\n<p>Antibiotic during first year of life </p>\n</td>\n<td>\n<p>α-Methyldopa</p>\n<p>Antibiotic during first year of life</p>\n</td>\n</tr>\n<tr>\n<td><strong>T cell involved</strong></td>\n<td>TH1 </td>\n<td>TH2</td>\n</tr>\n<tr>\n<td><strong>Gross findings/ endoscopic findings</strong></td>\n<td>\n<p>Transmural involvement</p>\n<p>Segmental involvement</p>\n<p>Skip lesions</p>\n<p>Cobblestone appearance</p>\n<p>Creeping fat</p>\n<p>Longitudinal ulcers</p>\n</td>\n<td>\n<p>Mucosal and superficial submucosal involvement </p>\n<p>Continuous involvement</p>\n<p>Pseudopolyps </p>\n<p>Backwash ileitis </p>\n<p>Collar button ulcers</p>\n</td>\n</tr>\n<tr>\n<td><strong>Earliest finding</strong></td>\n<td>Aphthous ulcer</td>\n<td>Erythematous mucosa with a fine granular surface</td>\n</tr>\n<tr>\n<td><strong>Microscopic findings </strong></td>\n<td>\n<p class=\"p1\">Deep, knife-like ulcers</p>\n<p>Granulomas</p>\n<p>Pyloric metaplasia  </p>\n</td>\n<td>\n<p class=\"p1\">Superficial, broad-based</p>\n<p>Cryptitis and crypt abscess </p>\n<p> </p>\n</td>\n</tr>\n<tr>\n<td><strong>Complications </strong></td>\n<td>\n<p>Fistulas </p>\n<p>Strictures</p>\n</td>\n<td>\n<p>Hemorrhage</p>\n<p>Toxic megacolon</p>\n</td>\n</tr>\n<tr>\n<td><strong>Recurrence after resection</strong></td>\n<td>\n<p>Common</p>\n</td>\n<td>\n<p>Uncommon, curative after resection</p>\n</td>\n</tr>\n<tr>\n<td><strong>Radiological findings </strong></td>\n<td>\n<p>Aphthous ulcer</p>\n<p>Rose thorn appearance</p>\n</td>\n<td>\n<p>Mucosal granularity</p>\n<p>Lead pipe appearance</p>\n</td>\n</tr>\n<tr>\n<td><strong>Extraintestinal manifestations</strong></td>\n<td colspan=\"2\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Episcleritis, uveitis </p>\n<p>Migratory polyarthritis</p>\n<p>Ankylosing spondylitis, sacroiliitis</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 807\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Erythema nodosum</p>\n<p>Pyoderma gangrenosum- MC in UC</p>\n<p>Primary sclerosing cholangitis- MC in UC</p>\n<p>Renal Calculi- MC in CD</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br /><br /></p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/21b6acc92e5b4e9a829425348b332c2c.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0309",
      "difficulty": "medium"
    },
    {
      "text": "Perianal examination of a patient revealed the following finding. Which condition is this associated with?",
      "choices": [
        {
          "id": 1,
          "text": "Ulcerative colitis"
        },
        {
          "id": 2,
          "text": "Crohn’s disease"
        },
        {
          "id": 3,
          "text": "Ischemic colitis"
        },
        {
          "id": 4,
          "text": "Ileocecal tuberculosis"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The above image shows a large<strong> hemorrhoidal perianal skin tag. </strong>These&nbsp;are found in patients with <strong>Crohn's disease</strong>,<strong>&nbsp;</strong>especially those with colon involvement.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/4341cba1f82b489fa904e3f6e0d276fd.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0344",
      "difficulty": "medium"
    },
    {
      "text": "A 28-year-old man was brought to the casualty with a high fever and abdominal pain for the past 2 days. His history is significant for bloody diarrhea over the past few months. The abdominal radiograph of this patient is given below. Identify the condition.",
      "choices": [
        {
          "id": 1,
          "text": "Toxic megacolon"
        },
        {
          "id": 2,
          "text": "Intussusception"
        },
        {
          "id": 3,
          "text": "Sigmoid volvulus"
        },
        {
          "id": 4,
          "text": "Pneumatosis intestinalis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The clinical scenario and radiograph are suggestive of<strong>&nbsp;toxic megacolon.&nbsp;</strong>It is seen in<strong> severe ulcerative colitis.&nbsp;</strong></p>\n<p>Abdominal radiography in toxic megacolon shows transverse or right colonic<strong> dilation &gt;6 cm </strong>and<strong> l</strong><strong>oss of haustrations.</strong></p>\n<p>Toxic megacolon may present with fever, abdominal pain, and abdominal distension or features of sepsis.&nbsp;</p><hr><h3>Related Pearl: Inflammatory Bowel Disease (IBD)</h3><p> </p>\n<table>\n<tbody>\n<tr>\n<td> </td>\n<td><strong>Crohn's disease</strong></td>\n<td><strong>Ulcerative colitis</strong></td>\n</tr>\n<tr>\n<td><strong>Age of onset </strong></td>\n<td>2nd-4th decades &amp; 7th-9th decades</td>\n<td>2nd-4th decades &amp; 7th-9th decades </td>\n</tr>\n<tr>\n<td><strong>Most common presentation</strong></td>\n<td>Ileocolitis with rectal sparing</td>\n<td>Proctitis (rectum)</td>\n</tr>\n<tr>\n<td><strong>Protective factors</strong></td>\n<td> None </td>\n<td>\n<p>Smoking </p>\n<p>Appendicectomy</p>\n</td>\n</tr>\n<tr>\n<td><strong>Risk factors</strong></td>\n<td>\n<p>OCP</p>\n<p>Smoking</p>\n<p>Antibiotic during first year of life </p>\n</td>\n<td>\n<p>α-Methyldopa</p>\n<p>Antibiotic during first year of life</p>\n</td>\n</tr>\n<tr>\n<td><strong>T cell involved</strong></td>\n<td>TH1 </td>\n<td>TH2</td>\n</tr>\n<tr>\n<td><strong>Gross findings/ endoscopic findings</strong></td>\n<td>\n<p>Transmural involvement</p>\n<p>Segmental involvement</p>\n<p>Skip lesions</p>\n<p>Cobblestone appearance</p>\n<p>Creeping fat</p>\n<p>Longitudinal ulcers</p>\n</td>\n<td>\n<p>Mucosal and superficial submucosal involvement </p>\n<p>Continuous involvement</p>\n<p>Pseudopolyps </p>\n<p>Backwash ileitis </p>\n<p>Collar button ulcers</p>\n</td>\n</tr>\n<tr>\n<td><strong>Earliest finding</strong></td>\n<td>Aphthous ulcer</td>\n<td>Erythematous mucosa with a fine granular surface</td>\n</tr>\n<tr>\n<td><strong>Microscopic findings </strong></td>\n<td>\n<p class=\"p1\">Deep, knife-like ulcers</p>\n<p>Granulomas</p>\n<p>Pyloric metaplasia  </p>\n</td>\n<td>\n<p class=\"p1\">Superficial, broad-based</p>\n<p>Cryptitis and crypt abscess </p>\n<p> </p>\n</td>\n</tr>\n<tr>\n<td><strong>Complications </strong></td>\n<td>\n<p>Fistulas </p>\n<p>Strictures</p>\n</td>\n<td>\n<p>Hemorrhage</p>\n<p>Toxic megacolon</p>\n</td>\n</tr>\n<tr>\n<td><strong>Recurrence after resection</strong></td>\n<td>\n<p>Common</p>\n</td>\n<td>\n<p>Uncommon, curative after resection</p>\n</td>\n</tr>\n<tr>\n<td><strong>Radiological findings </strong></td>\n<td>\n<p>Aphthous ulcer</p>\n<p>Rose thorn appearance</p>\n</td>\n<td>\n<p>Mucosal granularity</p>\n<p>Lead pipe appearance</p>\n</td>\n</tr>\n<tr>\n<td><strong>Extraintestinal manifestations</strong></td>\n<td colspan=\"2\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Episcleritis, uveitis </p>\n<p>Migratory polyarthritis</p>\n<p>Ankylosing spondylitis, sacroiliitis</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 807\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Erythema nodosum</p>\n<p>Pyoderma gangrenosum- MC in UC</p>\n<p>Primary sclerosing cholangitis- MC in UC</p>\n<p>Renal Calculi- MC in CD</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br /><br /></p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/130cd246bba54be5a6b7c5336787ec33.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0335",
      "difficulty": "easy"
    },
    {
      "text": "A patient with inflammatory bowel disease presents with ocular pain, photophobia, and blurred vision. Which among the following is the most likely cause?",
      "choices": [
        {
          "id": 1,
          "text": "Uveitis"
        },
        {
          "id": 2,
          "text": "Episcleritis"
        },
        {
          "id": 3,
          "text": "Scleritis"
        },
        {
          "id": 4,
          "text": "Conjunctivitis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Uveitis</strong> is the most common cause of the given symptoms in a patient with inflammatory bowel disease (IBD).</p>\n<p>Uveitis is an <strong>ophthalmic manifestation of IBD</strong>. It&nbsp;is associated with both ulcerative colitis and Crohn's disease. It can develop during remission and is seen even after bowel resection. Prompt intervention with <strong>glucocorticoids</strong> is required to prevent <strong>scarring</strong> and <strong>visual impairment.</strong></p>\n<p>The other common ophthalmic manifestations in IBD are <strong>conjunctivitis </strong>and<strong> episcleritis</strong>. Episcleritis, more common in Crohn's, is a benign disorder presenting with mild ocular burning.</p><hr><h3>Related Pearl: Inflammatory Bowel Disease (IBD)</h3><p> </p>\n<table>\n<tbody>\n<tr>\n<td> </td>\n<td><strong>Crohn's disease</strong></td>\n<td><strong>Ulcerative colitis</strong></td>\n</tr>\n<tr>\n<td><strong>Age of onset </strong></td>\n<td>2nd-4th decades &amp; 7th-9th decades</td>\n<td>2nd-4th decades &amp; 7th-9th decades </td>\n</tr>\n<tr>\n<td><strong>Most common presentation</strong></td>\n<td>Ileocolitis with rectal sparing</td>\n<td>Proctitis (rectum)</td>\n</tr>\n<tr>\n<td><strong>Protective factors</strong></td>\n<td> None </td>\n<td>\n<p>Smoking </p>\n<p>Appendicectomy</p>\n</td>\n</tr>\n<tr>\n<td><strong>Risk factors</strong></td>\n<td>\n<p>OCP</p>\n<p>Smoking</p>\n<p>Antibiotic during first year of life </p>\n</td>\n<td>\n<p>α-Methyldopa</p>\n<p>Antibiotic during first year of life</p>\n</td>\n</tr>\n<tr>\n<td><strong>T cell involved</strong></td>\n<td>TH1 </td>\n<td>TH2</td>\n</tr>\n<tr>\n<td><strong>Gross findings/ endoscopic findings</strong></td>\n<td>\n<p>Transmural involvement</p>\n<p>Segmental involvement</p>\n<p>Skip lesions</p>\n<p>Cobblestone appearance</p>\n<p>Creeping fat</p>\n<p>Longitudinal ulcers</p>\n</td>\n<td>\n<p>Mucosal and superficial submucosal involvement </p>\n<p>Continuous involvement</p>\n<p>Pseudopolyps </p>\n<p>Backwash ileitis </p>\n<p>Collar button ulcers</p>\n</td>\n</tr>\n<tr>\n<td><strong>Earliest finding</strong></td>\n<td>Aphthous ulcer</td>\n<td>Erythematous mucosa with a fine granular surface</td>\n</tr>\n<tr>\n<td><strong>Microscopic findings </strong></td>\n<td>\n<p class=\"p1\">Deep, knife-like ulcers</p>\n<p>Granulomas</p>\n<p>Pyloric metaplasia  </p>\n</td>\n<td>\n<p class=\"p1\">Superficial, broad-based</p>\n<p>Cryptitis and crypt abscess </p>\n<p> </p>\n</td>\n</tr>\n<tr>\n<td><strong>Complications </strong></td>\n<td>\n<p>Fistulas </p>\n<p>Strictures</p>\n</td>\n<td>\n<p>Hemorrhage</p>\n<p>Toxic megacolon</p>\n</td>\n</tr>\n<tr>\n<td><strong>Recurrence after resection</strong></td>\n<td>\n<p>Common</p>\n</td>\n<td>\n<p>Uncommon, curative after resection</p>\n</td>\n</tr>\n<tr>\n<td><strong>Radiological findings </strong></td>\n<td>\n<p>Aphthous ulcer</p>\n<p>Rose thorn appearance</p>\n</td>\n<td>\n<p>Mucosal granularity</p>\n<p>Lead pipe appearance</p>\n</td>\n</tr>\n<tr>\n<td><strong>Extraintestinal manifestations</strong></td>\n<td colspan=\"2\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Episcleritis, uveitis </p>\n<p>Migratory polyarthritis</p>\n<p>Ankylosing spondylitis, sacroiliitis</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 807\">\n<div class=\"page\" title=\"Page 807\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Erythema nodosum</p>\n<p>Pyoderma gangrenosum- MC in UC</p>\n<p>Primary sclerosing cholangitis- MC in UC</p>\n<p>Renal Calculi- MC in CD</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br /><br /></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0308",
      "difficulty": "medium"
    },
    {
      "text": "A 34-year-old man with Crohn’s disease presents with red tender swellings on the lower leg as shown below. What is the likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Pyoderma gangrenosum"
        },
        {
          "id": 2,
          "text": "Erythema nodosum"
        },
        {
          "id": 3,
          "text": "Sweet’s syndrome"
        },
        {
          "id": 4,
          "text": "Ecthyma gangrenosum"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario suggests a diagnosis of <strong>e</strong><strong>rythema nodosum</strong> seen in inflammatory bowel disease (IBD).&nbsp;</p>\n<p>Erythema nodosum is a dermatologic manifestation of IBD. It is<strong>&nbsp;</strong>seen in both ulcerative colitis and Crohn's disease. It manifests as <strong>tender erythematous</strong> <strong>nodules</strong> on the anterior surface of the lower legs, ankles, thighs, and arms.</p>\n<p>Option A: Pyoderma gangrenosum is a dermatological manifestation of IBD. It begins as pustular lesions which then ulcerate with necrotic foci and exudation.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/bab2382f5fbc42ff8a3041bfbe17124bx640x480.JPEG\" alt=\"Explanation Image\"><p>Option C: Sweet&rsquo;s syndrome is&nbsp;acute febrile neutrophilic dermatosis, seen in ulcerative colitis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e3143b2f02254c7ea92ecd571a79bc70x685x514.PNG\" alt=\"Explanation Image\"><p>Option D: Ecthyma gangrenosum is a&nbsp;skin infection caused by <em>Pseudomonas aeruginosa</em>, often seen in immunocompromised patients. It presents as pustules/vesicles which progress to necrotic ulcers.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c250c41b14fe4cee900baaf8dfb0f9c2x719x507.PNG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/3e402666312646af894043d450dac7a0.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1306",
      "difficulty": "medium"
    },
    {
      "text": "What are the cardiopulmonary manifestations associated with inflammatory bowel disease?<div class='question-desc-html'><ol>\n<li>Endocarditis</li>\n<li>VSD</li>\n<li>Pleuropericarditis</li>\n<li>Interstitial lung disease</li>\n<li>COPD</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1,2,5"
        },
        {
          "id": 2,
          "text": "4,5"
        },
        {
          "id": 3,
          "text": "2,3"
        },
        {
          "id": 4,
          "text": "1,3,4"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The cardiopulmonary manifestations of inflammatory bowel disease (IBD) are:</p>\n<ul>\n<li><strong>Endocarditis</strong></li>\n<li>Myocarditis</li>\n<li><strong>Pleuropericarditis</strong></li>\n<li><strong>Interstitial lung disease</strong></li>\n</ul>\n<p>Both ulcerative colitis and Crohn's disease have an increased risk of <strong>venous</strong> and <strong>arterial thrombosis.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0350",
      "difficulty": "medium"
    },
    {
      "text": "A 36-year-old man presents with worsening fatigue, jaundice, and pruritis for the last 3 months. Past history revealed recurrent episodes of bloody diarrhea and weight loss over the past year. Lab investigations show raised ALP, GGT, and bilirubin, and an MRCP is done as shown below. Which of the following is most likely to be associated with his current presentation?",
      "choices": [
        {
          "id": 1,
          "text": "Chronic pancreatitis"
        },
        {
          "id": 2,
          "text": "Celiac disease"
        },
        {
          "id": 3,
          "text": "Ulcerative colitis"
        },
        {
          "id": 4,
          "text": "Crohn’s disease"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The above clinical scenario along with MRCP showing multiple areas of intrahepatic narrowing with alternating areas of normal and dilated segments of bile ducts is suggestive of&nbsp;<strong>primary sclerosing cholangitis. </strong>PSC is more common in<strong> ulcerative colitis </strong>than in Crohn's disease.&nbsp;</p>\n<p>Additionally, recurrent episodes of bloody diarrhea with weight loss seen in this patient also point toward a possible diagnosis of ulcerative colitis.</p>\n<p>Primary sclerosing cholangitis (PSC) is an extraintestinal manifestation of IBD characterized by intrahepatic and extrahepatic duct inflammation/fibrosis. Around 50-75% of patients with <strong>primary sclerosing cholangitis</strong> (PSC) have inflammatory bowel disease (IBD) whereas, only 5% of IBD cases develop PSC.</p>\n<p>Option A: <strong>Chronic pancreatitis</strong> is associated with a&nbsp;<strong>chain of lakes</strong>&nbsp;appearance- dilated main duct with clubbing and dilatation of the side branches. Patients can present with&nbsp;<strong>steatorrhoea</strong>&nbsp;i.e., the passage of offensive-smelling large stools due to fat malabsorption.&nbsp;</p>\n<p>The image below shows <strong>chain of lakes</strong> appearance on MRI:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/11fbf2fa355a44b791013599b688a447x1280x1541.JPEG\" alt=\"Explanation Image\"><p>&nbsp;</p>\n<p>Option B: <strong>Celiac</strong> disease may be associated with&nbsp;primary biliary cholangitis (<strong>PBC</strong>), rather than primary sclerosing cholangitis.</p><hr><h3>Related Pearl: Differences between primary sclerosing cholangitis (PSC)  and primary biliary cholangitis (PBC)</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Primary Biliary Cholangitis</strong></td>\n<td><strong>Primary Sclerosing Cholangitis</strong></td>\n</tr>\n<tr>\n<td>Antibodies</td>\n<td>\n<p>Antimitochondrial antibodies positive in most patients</p>\n<p>Antinuclear antibodies positive</p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 860\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Antimitochondrial antibodies /AMA typically negative</p>\n</div>\n</div>\n</div>\n</div>\n<p><strong>p-ANCA</strong>-positive</p>\n</td>\n</tr>\n<tr>\n<td>Age group</td>\n<td>40&ndash;60 years</td>\n<td>30-45 years</td>\n</tr>\n<tr>\n<td>Gender predominance</td>\n<td>Females</td>\n<td>Males</td>\n</tr>\n<tr>\n<td>Site</td>\n<td>Intrahepatic&nbsp;bile ducts only</td>\n<td>Intra- and extrahepatic bile ducts</td>\n</tr>\n<tr>\n<td>&nbsp;Associated with</td>\n<td>\n<p>Sjogren syndrome</p>\n<p>Hashimoto's thyroiditis&nbsp;</p>\n<p>CREST&nbsp;syndrome</p>\n<p>Rheumatoid arthritis</p>\n<p>Celiac disease</p>\n</td>\n<td><strong>Ulcerative colitis</strong></td>\n</tr>\n<tr>\n<td>Diagnosis</td>\n<td>Biopsy</td>\n<td>MRCP/ERCP-strictures&nbsp;</td>\n</tr>\n<tr>\n<td>Biopsy findings</td>\n<td>&nbsp;<strong>Florid duct lesion</strong> (granuloma)</td>\n<td>Concentric \"<strong>onion-skin\"</strong>&nbsp;fibrosis &nbsp; &nbsp;</td>\n</tr>\n<tr>\n<td>Long-term complication</td>\n<td>Cirrhosis</td>\n<td>\n<p>Cirrhosis</p>\n<p>Cholangiocarcinoma</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/57458a2351b14376b5e4cc3c64da1b13.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1310",
      "difficulty": "easy"
    },
    {
      "text": "After initiating treatment for patients with IBD, in which of the following extraintestinal manifestations would you expect to see an improvement?",
      "choices": [
        {
          "id": 1,
          "text": "Arthritis"
        },
        {
          "id": 2,
          "text": "Ankylosing spondylitis"
        },
        {
          "id": 3,
          "text": "Uveitis"
        },
        {
          "id": 4,
          "text": "Pyoderma gangrenosum"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>A</strong><strong>rthritis </strong>worsens with exacerbation of bowel disease and <strong>improves</strong> with the <strong>treatment</strong> of bowel symptoms or surgery.</p>\n<p>Ankylosing spondylitis, uveitis, and pyoderma gangrenosum do not correlate with disease activity in the bowel. They may occur during the remission of disease or even after surgery.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1309",
      "difficulty": "medium"
    },
    {
      "text": "A patient is diagnosed with ulcerative colitis on endoscopy. He is hemodynamically stable but currently has 3-4 episodes of blood-tinged loose stools per day.  Which of the following drug would you prefer for treating this patient?",
      "choices": [
        {
          "id": 1,
          "text": "5-aminosalicylic acid"
        },
        {
          "id": 2,
          "text": "Azathioprine"
        },
        {
          "id": 3,
          "text": "Budesonide"
        },
        {
          "id": 4,
          "text": "6-mercaptopurine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The above scenario is suggestive of <strong>mild ulcerative colitis</strong>. The preferred drug for mild ulcerative colitis (UC) is <strong>5-ASA agents </strong>(5-aminosalicylic acid). </p>\n<p>Given below is the <strong>Truelove and Witts severity index</strong> for ulcerative colitis. </p>\n<table>\n<tbody>\n<tr>\n<td> </td>\n<td><strong>Mild</strong></td>\n<td><strong>Moderate</strong></td>\n<td><strong>Severe</strong></td>\n</tr>\n<tr>\n<td>Bowel movements</td>\n<td>&lt; 4 per day</td>\n<td>4 – 6 per day</td>\n<td>&gt; 6 per day</td>\n</tr>\n<tr>\n<td>Blood in stool</td>\n<td>Small</td>\n<td>Moderate</td>\n<td>Severe</td>\n</tr>\n<tr>\n<td>Fever</td>\n<td>None</td>\n<td>&lt; 37.5ºC</td>\n<td>&gt; 37.5ºC</td>\n</tr>\n<tr>\n<td>Tachycardia</td>\n<td>None</td>\n<td>&lt; 90 mean pulse</td>\n<td>&gt;90 mean pulse</td>\n</tr>\n<tr>\n<td>Anemia</td>\n<td>Mild</td>\n<td>Hb &gt; 75% of normal Hb</td>\n<td>Hb &lt; 75% of normal Hb</td>\n</tr>\n<tr>\n<td>ESR</td>\n<td>&lt; 30mm</td>\n<td> &lt; 30mm</td>\n<td> &gt; 30mm</td>\n</tr>\n<tr>\n<td>Endoscopic appearance</td>\n<td>\n<p>Erythema</p>\n<p>Decreased vascular markings</p>\n<p>Fine granularity</p>\n</td>\n<td>\n<p>Marked erythema</p>\n<p>Absent vascular markings</p>\n<p>Coarse granularity</p>\n<p>Contact bleeding</p>\n<p>No ulcerations</p>\n</td>\n<td>\n<p>Spontaneous bleeding</p>\n<p>Ulcerations</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"4\"><strong>Treatment of Ulcerative Colitis</strong></td>\n</tr>\n<tr>\n<td> </td>\n<td><strong>Mild </strong></td>\n<td><strong>Moderate</strong></td>\n<td><strong>Severe</strong></td>\n</tr>\n<tr>\n<td><strong>Induction</strong></td>\n<td>5-ASA</td>\n<td>5-ASA + Oral steroids</td>\n<td>IV steroids + IV anti TNF alpha + IV cyclosporine</td>\n</tr>\n<tr>\n<td><strong>Maintainance</strong></td>\n<td>5-ASA</td>\n<td>5-ASA + Azathioprine/6-MP</td>\n<td>Oral cyclosporine or infliximab</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>\n<p>Note: Mirikizumab ( an IL-23 inhibitor) was recently FDA approved for the treatment of moderate to severe ulcerative colitis. It reduces stool frequency, rectal bleeding and bowel urgency.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0356",
      "difficulty": "easy"
    },
    {
      "text": "A 36-year-old man presented with complaints of 7-8 episodes of bloody diarrhea per day. He is pale and febrile. Heart rate is 110 bpm and ESR is 50mm. Colonoscopy revealed continuous mucosal involvement with ulcerations and mucosal hemorrhages. Which of the following drugs would you not prefer in the management of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Mesalamine"
        },
        {
          "id": 2,
          "text": "Infliximab"
        },
        {
          "id": 3,
          "text": "IV steroids"
        },
        {
          "id": 4,
          "text": "Cyclosporine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The above scenario is suggestive of <strong>severe ulcerative colitis. Mesalamine </strong>(5-ASA) is ineffective in the management of severe ulcerative colitis (UC). It is used in the treatment of <strong>mild-moderate UC.</strong></p>\n<p>Given below is the <strong>Truelove and Witts severity index</strong> for ulcerative colitis. </p>\n<table>\n<tbody>\n<tr>\n<td> </td>\n<td><strong>Mild</strong></td>\n<td><strong>Moderate</strong></td>\n<td><strong>Severe</strong></td>\n</tr>\n<tr>\n<td>Bowel movements</td>\n<td>&lt; 4 per day</td>\n<td>4 – 6 per day</td>\n<td>&gt; 6 per day</td>\n</tr>\n<tr>\n<td>Blood in stool</td>\n<td>Small</td>\n<td>Moderate</td>\n<td>Severe</td>\n</tr>\n<tr>\n<td>Fever</td>\n<td>None</td>\n<td>&lt; 37.5ºC</td>\n<td>&gt; 37.5ºC</td>\n</tr>\n<tr>\n<td>Tachycardia</td>\n<td>None</td>\n<td>&lt; 90 mean pulse</td>\n<td>&gt;90 mean pulse</td>\n</tr>\n<tr>\n<td>Anemia</td>\n<td>Mild</td>\n<td>Hb &gt; 75% of normal Hb</td>\n<td>Hb &lt; 75% of normal Hb</td>\n</tr>\n<tr>\n<td>ESR</td>\n<td>&lt; 30mm</td>\n<td> &lt; 30mm</td>\n<td> &gt; 30mm</td>\n</tr>\n<tr>\n<td>Endoscopic appearance</td>\n<td>\n<p>Erythema</p>\n<p>Decreased vascular markings</p>\n<p>Fine granularity</p>\n</td>\n<td>\n<p>Marked erythema</p>\n<p>Absent vascular markings</p>\n<p>Coarse granularity</p>\n<p>Contact bleeding</p>\n<p>No ulcerations</p>\n</td>\n<td>\n<p>Spontaneous bleeding</p>\n<p>Ulcerations</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"4\">Treatment of Ulcerative Colitis   </td>\n</tr>\n<tr>\n<td> </td>\n<td>Mild </td>\n<td>Moderate</td>\n<td>Severe</td>\n</tr>\n<tr>\n<td>Induction</td>\n<td>5-ASA</td>\n<td>5-ASA + Oral steroids</td>\n<td>IV steroids + IV anti TNF alpha + IV cyclosporine</td>\n</tr>\n<tr>\n<td>Maintainance</td>\n<td>5-ASA</td>\n<td>5-ASA + Azathioprine/6-MP</td>\n<td>Oral cyclosporine or infliximab</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>\n<p>Note: Mirikizumab ( an IL-23 inhibitor) was recently FDA approved for the treatment of moderate to severe ulcerative colitis. It reduces stool frequency, rectal bleeding and bowel urgency.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1305",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs have no role in the management of patients with ulcerative colitis?",
      "choices": [
        {
          "id": 1,
          "text": "Oral salicylates"
        },
        {
          "id": 2,
          "text": "Hydrocortisone"
        },
        {
          "id": 3,
          "text": "Metronidazole"
        },
        {
          "id": 4,
          "text": "Cyclosporine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Metronidazole</strong> has no role in the management of ulcerative colitis. It is an antibiotic that is useful in active inflammatory, fistulous, and perianal <strong>Crohn's disease</strong>.</p>\n<p>Note: Mirikizumab ( an IL-23 inhibitor) was recently FDA approved for the treatment of moderate to severe ulcerative colitis. It reduces stool frequency, rectal bleeding and bowel urgency.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1307",
      "difficulty": "easy"
    },
    {
      "text": "A patient with Crohn's disease is started on infliximab. Which of the following conditions is the patient is at increased risk of developing?",
      "choices": [
        {
          "id": 1,
          "text": "Hodgkin’s Lymphoma"
        },
        {
          "id": 2,
          "text": "Non-Hodgkin lymphoma"
        },
        {
          "id": 3,
          "text": "Hairy cell Leukaemia"
        },
        {
          "id": 4,
          "text": "Follicular lymphoma"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Patients with&nbsp;<strong>Crohn's disease </strong>on<strong> infliximab</strong> are at increased risk of <strong>non-Hodgkin lymphoma</strong>&nbsp;(NHL) and<strong>&nbsp;hepatosplenic T-cell lymphoma </strong>(HS-TCL).</p>\n<p>Infliximab&nbsp;is the first<strong>&nbsp;biologic therapy</strong>&nbsp;approved for&nbsp;Crohn's disease. It is an&nbsp;IgG1 antibody against<strong> TNF-alpha</strong>.&nbsp;</p>\n<p>Drugs used in treatment of Crohn&rsquo;s disease:</p>\n<ol>\n<li aria-level=\"1\">Oral budesonide (mainly for mild to moderate)</li>\n<li aria-level=\"1\">Oral prednisolone</li>\n<li aria-level=\"1\">Methotrexate</li>\n<li aria-level=\"1\">Anti TNF alpha</li>\n<li aria-level=\"1\">Azathioprine</li>\n<li aria-level=\"1\">6-mercaptopurine</li>\n<li aria-level=\"1\">Monoclonal antibodies</li>\n<li aria-level=\"1\">Antibiotics</li>\n</ol>\n<p>Infliximab is also used in the&nbsp;treatment of moderate to severely active ulcerative colitis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0359",
      "difficulty": "medium"
    },
    {
      "text": "Ustekinumab is effective in all of the following conditions except:",
      "choices": [
        {
          "id": 1,
          "text": "Rheumatoid arthritis"
        },
        {
          "id": 2,
          "text": "Ulcerative colitis"
        },
        {
          "id": 3,
          "text": "Psoriatic arthirtis"
        },
        {
          "id": 4,
          "text": "Crohn's disease"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Ustekinumab</strong> has no role in rheumatoid arthritis. It is effective against both <strong>Crohn's disease </strong>and <strong>ulcerative colitis</strong>.</p>\n<p>It can also be used in the management of plaque psoriasis and <strong>psoriatic</strong> <strong>arthritis</strong>.</p>\n<p>It is an IgG1 monoclonal antibody that <strong>blocks </strong>the activity of<strong> IL-12 </strong>and<strong> IL-23.</strong></p>\n<p>Biological therapy in inflammatory bowel disease:</p>\n<ul>\n<li>Anti-TNF therapies:\n<ul>\n<li>Infliximab</li>\n<li>Adalimumab</li>\n<li>Certolizumab</li>\n</ul>\n</li>\n<li>Anti-integrins:\n<ul>\n<li>Natalizumab</li>\n<li>Ustekinumab</li>\n<li>Vedolizumab</li>\n</ul>\n</li>\n</ul>\n<p>Note: Mirikizumab (an IL-23 inhibitor) was recently FDA approved for the treatment of moderate to severe ulcerative colitis. It reduces stool frequency, rectal bleeding and bowel urgency.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0361",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following drugs has no role after induction of remission has been achieved in a patient with IBD?",
      "choices": [
        {
          "id": 1,
          "text": "5-ASA agents"
        },
        {
          "id": 2,
          "text": "Glucocorticoids"
        },
        {
          "id": 3,
          "text": "Azathioprine"
        },
        {
          "id": 4,
          "text": "Infliximab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Glucocorticoids</strong> play <strong>no role in maintenance </strong>therapy in&nbsp;inflammatory bowel disease.</p>\n<p>They are used for <strong>induction in Crohn's disease</strong> and <strong>moderate to severe ulcerative colitis</strong>. Once clinical remission has been induced, they should be tapered gradually.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1308",
      "difficulty": "medium"
    },
    {
      "text": "A patient with IBD was brought to the ER with acute epigastric pain radiating to the back. His lab investigations revealed elevated serum amylase and lipase. He gives a history of being started on a new drug for maintenance therapy of his IBD 2 weeks back. The causative drug is most likely to be:",
      "choices": [
        {
          "id": 1,
          "text": "Methotrexate"
        },
        {
          "id": 2,
          "text": "Tacrolimus"
        },
        {
          "id": 3,
          "text": "5-ASA"
        },
        {
          "id": 4,
          "text": "Azathioprine"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The above scenario is suggestive of <strong>pancreatitis.&nbsp;Azathioprine </strong>causes pancreatitis in some patients within the <strong>first few weeks of therapy</strong>. It is completely <strong>reversible</strong> on discontinuing the drug.</p>\n<p>Azathioprine and 6-mercaptopurine (purine analogues) also have an increased risk of toxicity as some individuals may lack the enzyme necessary for their metabolism. This may lead to hepatitis, bone marrow suppression, etc. Hence, the patient should be monitored regularly with blood counts and liver function tests.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0352",
      "difficulty": "medium"
    },
    {
      "text": "What is nutritional therapy in inflammatory bowel disease used for?",
      "choices": [
        {
          "id": 1,
          "text": "Maintaining remission in Crohn's disease"
        },
        {
          "id": 2,
          "text": "Maintaining remission in ulcerative colitis"
        },
        {
          "id": 3,
          "text": "Inducing remission in Crohn's disease"
        },
        {
          "id": 4,
          "text": "Inducing remission in ulcerative colitis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Nutritional therapy</strong> is used for <strong>inducing&nbsp;remission </strong>in<strong> Crohn's disease</strong>.</p>\n<p>Dietary antigens may stimulate an immune response. Hence, nutritional therapies like <strong>total parenteral nutrition</strong>, enteral nutrition (peptide-based preparations), etc. can be used to <strong>provide bowel rest</strong> in active Crohn's disease. These interventions cannot be used for maintaining remission.</p>\n<p>Ulcerative colitis does not respond to dietary intervention.</p>\n<p>Drugs used in treatment of Crohn&rsquo;s disease:</p>\n<ol>\n<li aria-level=\"1\">Oral budesonide (mainly for mild to moderate)</li>\n<li aria-level=\"1\">Oral prednisolone</li>\n<li aria-level=\"1\">Methotrexate</li>\n<li aria-level=\"1\">Anti TNF alpha</li>\n<li aria-level=\"1\">Azathioprine</li>\n<li aria-level=\"1\">6-mercaptopurine</li>\n<li aria-level=\"1\">Monoclonal antibodies</li>\n<li aria-level=\"1\">Antibiotics</li>\n</ol>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0393",
      "difficulty": "hard"
    },
    {
      "text": "What is the treatment of choice in a patient with refractory ulcerative colitis?",
      "choices": [
        {
          "id": 1,
          "text": "Mucosal proctectomy with ileal pouch–anal anastomosis"
        },
        {
          "id": 2,
          "text": "Proctectomy with ileorectal anastomosis"
        },
        {
          "id": 3,
          "text": "Colectomy with ileostomy"
        },
        {
          "id": 4,
          "text": "Ileorectal anastomosis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The treatment of choice in refractory ulcerative colitis (UC) is&nbsp;<strong>mucosal proctectomy</strong>&nbsp;with<strong> ileal pouch&ndash;anal anastomosis&nbsp;(IPAA)</strong>.</p>\n<p>As ulcerative colitis is a mucosal disease, the rectal mucosa is dissected and removed down to the dentate line of the anus. The ileum is made into a pouch that serves as neorectum.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0354",
      "difficulty": "medium"
    }
  ]
}